Recent Progress in HIV-1 Inhibitors Targeting the Entrance Channel of HIV-1 Non-nucleoside Reverse Transcriptase Inhibitor Binding Pocket
Overview
Affiliations
Since the entrance channel was proposed as a new binding site in non-nucleoside reverse transcriptase inhibitor binding pocket (NNIBP) of HIV-1 reverse transcriptase (RT) in 2012, a huge number of HIV-1 inhibitors acting on this target have sprung up, aiming to discover promising inhibitors with excellent antiviral activities, physicochemical properties, and so on. From 2012 to 2018, many noteworthy compounds have been continuously discovered. In this review, the recent progress in HIV-1 inhibitors targeting the entrance channel of HIV-1 NNIBP was summarized and reviewed, which would provide useful clues and inspiration for further design of HIV-1 inhibitors.
Prener L, Baszczynski O, Kaiser M, Dracinsky M, Stepan G, Lee Y J Med Chem. 2023; 66(3):1761-1777.
PMID: 36652602 PMC: 10017027. DOI: 10.1021/acs.jmedchem.2c01574.
Approved HIV reverse transcriptase inhibitors in the past decade.
Li G, Wang Y, De Clercq E Acta Pharm Sin B. 2022; 12(4):1567-1590.
PMID: 35847492 PMC: 9279714. DOI: 10.1016/j.apsb.2021.11.009.
Design of Novel HIV-1 NNRTIs Based on Combined Modeling Studies of Dihydrofuro[3,4-d]pyrimidines.
Chen Y, Tian Y, Gao Y, Wu F, Luo X, Ju X Front Chem. 2020; 8:164.
PMID: 32266208 PMC: 7105726. DOI: 10.3389/fchem.2020.00164.
Jin K, Liu M, Zhuang C, De Clercq E, Pannecouque C, Meng G Acta Pharm Sin B. 2020; 10(2):344-357.
PMID: 32082978 PMC: 7016291. DOI: 10.1016/j.apsb.2019.09.007.